We report the clinical, pathologic, and biochemical characteristics of the recently described amyloid precursor protein (APP) I716F mutation. We present the clinical findings of individuals carrying the APP I716F mutation and the neuropathologic examination of the proband. The mutation was found in a patient with Alzheimer disease with onset at the age of 31 years and death at age 36 years and who had a positive family history of early-onset Alzheimer disease. Neuropathologic examination showed abundant diffuse amyloid plaques mainly composed of amyloid-A 42 and widespread neurofibrillary pathology. Lewy bodies were found in the amygdala. Chinese hamster ovary cells transfected with this mutation showed a marked increase in the amyloid-A 42/40 ratio and APP C-terminal fragments and a decrease in APP intracellular domain production, suggesting reduced APP proteolysis by F-secretase. Taken together, these findings indicate that the APP I716F mutation is associated with the youngest age of onset for this locus and strengthen the inverse association between amyloid-A 42/40 ratio and age of onset. The mutation leads to a protein that is poorly processed by F-secretase. This loss of function may be an additional mechanism by which some mutations around the F-secretase cleavage site lead to familial Alzheimer disease.
INTRODUCTION
The genes of amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) have been implicated in the pathogenesis of familial Alzheimer disease (FAD). Mutations in the PSEN1 gene represent the most common cause of FAD (1) , and more than 175 mutations have been identified to date (www.molgen.ua.ac.be/ADMutations). Mutations in the APP gene are rare but provide insight into the pathogenesis of FAD. All APP pathogenic mutations are located either in the amyloid-A (AA) sequence or in the vicinity of a protease cleavage site that influences APP proteolysis by different mechanisms. The Swedish APP mutation, adjacent to the A-cleavage site, increases the production of total AA by enhancing APP cleavage by A-secretase (2, 3) . APP mutations within the AA sequence (e.g. the Arctic and Iowa mutations) cause severe cerebral amyloid angiopathy or Alzheimer disease (AD) (4Y8) by enhancing the tendency of the AA peptide to aggregate (7, 9) or by increasing its resistance to proteolytic degradation (10, 11) . Mutations near the F-secretase cleavage site such as the London (V717I, V717G), Indiana (V717F), and Florida (I716V) mutations lead to an increase in the amyloidogenic AA 
(12Y17).
Amyloid precursor protein has been shown to be cleaved by F-secretase through a series of sequential cleavage steps. First, there is ?-cleavage near the membrane-cytoplasm boundary, followed by F-cleavage in the middle of the transmembrane domain (18) . The ?-cleavage results in the release of an APP intracellular domain (AICD), whereas the F-cleavage results in the generation of AA peptides (19Y21). Several AA species consisting of 36 to 43 residues are generated and constitutively secreted. AA 40 is the most predominant species, and although AA 42 is a minor one, it predominates in the diffuse and mature plaques found in AD (22) .
Most studies on APP mutations near F-secretase cleavage site have focused on the ratio AA 42/40 as the main mechanism by which these mutations exert their pathogenic effects (15, 17, 23) . Here, we describe the clinical, neuropathologic, and biochemical characteristics of the recently described APP I716F mutation (24) . This family shows the youngest age of onset for this locus, an aggressive clinical course, and severe neuropathologic phenotype. Biochemical experiments confirmed a marked increased in AA 42/40 ratio and reduced APP proteolysis by F-secretase.
MATERIALS AND METHODS

Neuropathologic Examination
sensory, parietal, temporal superior, temporal inferior, anterior cingulate, anterior insular, and primary and associative visual cortices, entorhinal cortex and hippocampus, caudate, putamen and pallidum, medial and posterior thalamus, subthalamus, nucleus basalis of Meynert, amygdala, midbrain (2 levels), pons, medulla oblongata, cerebellar cortex, and dentate nucleus were examined. Dewaxed sections (5-Km thick) were stained with hematoxylin and eosin and with Klüver-Barrera, or were processed for immunohistochemistry using the EnVision+ system peroxidase procedure (DAKO, Barcelona, Spain). After incubation with methanol and normal serum, the sections were incubated with 1 of the primary antibodies at 4-C overnight. Antibodies to glial fibrillary acidic protein (DAKO), AA (Boehringer, Barcelona, Spain), and ubiquitin (DAKO) were used at dilutions of 1:250, 1:50, and 1:200, respectively. Antibodies to AA and AA (a generous gift from Dr. Sarasa, Zaragoza, Spain) were used at dilutions of 1:50. Antibodies to >-synuclein (Chemicon, Barcelona, Spain) were used at a dilution of 1:3000. Monoclonal anti-phospho-tau AT8 (Innogenetics, Gent, Belgium) was diluted 1:50. Phospho-specific tau rabbit polyclonal antibodies Thr181, Ser199, Ser202, Ser214, Ser231, Ser262, Ser396, and Ser422 (all from Calbiochem, Torrey Pines, CA) were used at a dilution of 1:100 except for anti-phospho-tauThr181, which was used at a dilution of 1:250. Antibodies to 3R and 4R tau (Upstate, Millipore, Barcelona, Spain) were used at dilutions 1:800 and 1:50, respectively. TAR DNA binding protein was examined using a mouse monoclonal antibody (Abnova, TebuBio, Barcelona, Spain) at a dilution of 1:1000, and a rabbit polyclonal antibody (Abcam, Cambridge, UK) at a dilution of 1:2000. PhosphoYTAR DNA binding protein was studied by using a mouse monoclonal antibody at a dilution of 1:5000 and a rabbit polyclonal antibody at a dilution of 1:2500 (both from Cosmo Bio Co., Ltd., Koto-ku, Japan). The peroxidase reaction was visualized with 0.05% diaminobenzidine and 0.01% H 2 O 2 . Sections were counterstained with hematoxylin. Sections processed for phospho-tau immunohistochemistry were boiled in citrate buffer before incubation with the primary antibody. Sections processed for AA and >-synuclein were pretreated with 95% formic acid.
Cell Culture and Transfections
Chinese hamster ovary (CHO) cells were cultured in Dulbecco's Modified Eagle Medium (Invitrogen, Carlsbad, CA) with 10% fetal bovine serum at 37-C with 5% CO 2 in a tissue culture incubator. Cells were transfected using Fugene reagent (Invitrogen) according to the manufacturer's instructions.
Plasmid Construction
Mutated cDNA constructs encoding APP V717I and APP I716F were introduced in human wild-type APP 695 cDNA by site-directed mutagenesis (Stratagene, Cedar Creek, TX).
AA Enzyme-Linked Immunosorbent Assay
Conditioned medium was collected 24 hours after transfection. Human AA was measured by ELISA, as described (26) . Briefly, antibody 6E10 (against AA 1Y17 ; Chemicon, Temecula, CA) was used as a capture antibody and a rabbit polyclonal AA (Chemicon) as a detection antibody. After incubation for 3 hours, wells were washed with PBS and a horseradish peroxidaseYconjugated donkey anti-rabbit antibody (Jackson Laboratories, West Grove, PA) was added. Wells were washed with PBS, Quantablue reagent (Pierce, Rockford, IL) was added, and samples were read at 320 nm using a Victor3 Wallac plate reader (Perkin-Elmer, Waltham, MA). Human AA and AA 1-x (as a measure of total AA) were detected using sensitive ELISA kits (Wako, Osaka, Japan, and IBL, Hamburg, Germany, respectively).
Membrane Preparations and Cell-Free AICD Generation Assay
For Western blot analysis of the APP C-terminal fragments (CTFs), cellular membranes were isolated from CHO cells transfected with wild-type, V717I, or I716F APP constructs, as described (27) . For the brain samples, 100 to 200 mg of tissue was homogenized with the Proteo Extract Native Membrane Protein Extraction Kit (Calbiochem). Amyloid precursor protein intracellular domain was generated in vitro from membrane preparations of transfected CHO cells, as described (19) . The samples were electrophoresed in 5% to 16% Tris-Tricine gels, transferred to 0.2-Km nitrocellulose membranes, and detected by immunoblotting with a rabbit anti-APP C-terminal (Sigma-Aldrich, St. Louis, MO) antibody.
F-Secretase Activity
F-Secretase activity in cell lysates was measured by a fluorometric activity Kit (R&D Systems, Minneapolis, MN).
Statistical Analysis
One-way analysis of variance was performed to analyze differences in AA levels, APP CTFs, and F-secretase activity, followed by least significant difference post hoc analysis. Levene test was also performed to determine whether variances were equal.
RESULTS
Family History
The proband was a 33-year-old man who complained of a progressive history of forgetfulness and difficulties in concentrating, with the onset of symptoms at age 31 years (Fig. 1A) . He had problems in remembering recent events and with abstract reasoning. Over the next 2 years, he showed difficulties planning, using utensils, and performing fine-hand sequences that interfered with his work as a gardener. He also displayed difficulties with the sense of direction, and as a result, he had to stop working and driving. Occasionally, he complained of irregular jerks in both arms. Neuropsychologic evaluation at the age of 33 years showed deficits in verbal and visual memory, attention, and calculating with marked motor and constructive apraxia. His Mini Mental State Examination score was 21 of 30. Brain magnetic resonance imaging at the age of 33 years showed bilateral atrophy in frontoparietal regions.
99m
Tc-Hexamethylpropyleneamine oxime brain perfusion single-photon emission computerized tomography showed hypoperfusion in both parietal regions (Fig. 1B) . The patient continued to worsen and died at the age of 36 years. The father's proband had developed dementia at the age of 35 years. A brain biopsy at the age of 39 years showed abundant diffuse and neuritic plaques, amyloid angiopathy, and neurofibrillary tangles immunoreactive for phosphorylated tau. The diagnosis made was AD, and he died at the age of 41 years. We were unable to investigate family history of dementia because he had been adopted. The proband's sibling is cognitively normal and refused genetic testing. There was no other family history of dementia. Genetic screening of the coding regions of PSEN1, PSEN2, and APP genes in the proband disclosed an APP I716F mutation ( Fig. 1C; [24] ). APOE genotype was ?3?3.
Neuropathologic Examination of the Proband
Neuropathologic evaluation showed global cerebral atrophy. Microscopic examination revealed extensive diffuse and neuritic perineuronal AA plaques, subpial deposits, and cerebral amyloid angiopathy. Neuritic plaques, composed mainly of AA and AA , predominated in the entorhinal cortex, subiculum, hippocampus, amygdala, and inner region of the temporal and orbitofrontal cortex (Fig. 2AYC) . In contrast, diffuse plaques, perineuronal plaques, and subpial AA deposits were mainly stained with antibodies to AA ( Fig. 2DYF ) and were present in most of the neocortex. Cerebral amyloid angiopathy affected small arteries, arterioles, and venules of the meninges and the brain (Fig. 2B) ; capillaries were spared. Neurofibrillary tangles and neuropil threads were present in large numbers in the entorhinal and transentorhinal cortices, hippocampus, amygdala, nucleus basalis of Meynert, septal nuclei, and the entire cerebral neocortex, including the primary sensory and motor areas (Fig. 2G, H) . Neurofibrillary tangles were also present in selected nuclei of the brainstem, including the substantia nigra, motor ocular nuclei, locus ceruleus, and reticular formation of the pons and medulla oblongata. Dystrophic neurites containing hyperphosphorylated tau were abundant in the amygdala, hippocampus, and entorhinal cortex, corresponding to AD Stage VI of Braak. All of these structures were stained with AT8, other phospho-specific anti-tau antibodies, and with anti-4R (Fig. 2G) , anti-3R (Fig. 2H) , and anti-ubiquitin antibodies.
>-Synuclein immunoreactivity was observed in the amygdala in the form of large numbers of Lewy bodies and aberrant neurites (Fig. 2I) . TAR DNA binding proteinY immunoreactive inclusions were absent. Neuronal loss, astrocytic gliosis, and microgliosis were moderate in the cerebral neocortex but were more marked in the entorhinal and perirhinal cortex, subiculum, and amygdala. Astrocytes predominated in the inner cortical layers of the neocortex, plexiform layers of the hippocampus, and around neuritic plaques. Likewise, microglia were increased in number in the cerebral cortex and white matter and more abundantly around neuritic plaques.
Biochemical Effects of the APP I716F Mutation
We next investigated the effects of this mutation on APP processing in transfection studies using CHO cells. Quantitative analysis of the major AA species in the conditioned medium from APP I716FYtransfected CHO cells showed increased (È2-fold) AA 42 , reduced (È0.5-fold) AA 40 , and total AA (È0.5-fold) levels compared with those of wildtype APP (Fig. 3A) . As a result, the AA 42/40 ratio was markedly increased (È4-fold) in cells transfected with the APP I716F mutation (Fig. 3B) . Results were compared with cells transfected with the adjacent APP V717I mutation (13) , which led to similar but milder effects. Membrane preparations from APP I716FY and V717IYtransfected cells showed a marked increase (2-and 2.5-fold) in APP CTFs compared with that of wild-type APP (Fig. 4A) . Interestingly, the levels of APP CTFs were higher in the proband's brain homogenates than in sporadic AD patients or young and elderly healthy controls (Fig. 4B) . Incubation of membrane preparations from APP I716F-and V717I-transfected cells showed a reduced production of AICD and accumulation of CTFs (Fig. 4C) . Finally, lysates from cells transfected with APP I716F or V717I mutations showed reduced F-secretase activity assessed by a fluorogenic kit assay (Fig. 4D) .
DISCUSSION
The APP I716F mutation had previously been described as an artificial mutation with extreme effects on the AA 42/40 ratio (23, 28Y30). Here, we describe the full clinical, neuropathologic, and biochemical profile of the recently reported APP I716F mutation (24) . This FAD mutation is associated with the youngest age of onset for this locus (mean age of onset, 49 years [31] ), supporting the strong inverse association between AA 42/40 ratio and age of onset (17) . Neuropathologic study of the proband's brain revealed atypical generalized and extensive AA deposition in the brain and cerebral blood vessels. Amyloid-A deposition formed neuritic plaques in the inner regions of the temporal lobe and large numbers of AA 1-42 -predominant diffuse plaques, perineuronal plaques, and subpial deposits in the neocortex. As in other families with APP mutations (32, 33) , as well as in sporadic AD cases (34) , Lewy bodies were observed in the amygdala, suggesting that >-synuclein pathology is downstream of AA 1-42 deposition in these families. However, the reasons for such selective involvement are not known.
Biochemical characterization of this mutation extended previously described results (23, 28Y30) . The APP I716F mutation leads to a marked increase in AA 42 and the AA 42/40 ratio and reduced AA 40 and AA 1-x levels. As expected, the AA 42/40 ratio was lower than other studies that used APP C99 (which is the direct substrate for F-secretase) for transfection studies (23, 28, 29) . As for other APP mutations located near the F-secretase cleavage site (17, 35) , we also showed that the APP I716F mutation led to a prominent accumulation of APP CTFs in transfected cells. Interestingly, APP CTFs were higher in the proband's brain homogenates than in sporadic AD patients and healthy controls. Although the availability of only a single brain sample precluded an in-depth analysis of APP processing in this kindred, this increase suggests that APP CTF accumulation is not an artifact in the cellular model. However, the increase in APP CTFs does not necessarily reflect reduced F-secretase activity because it has been observed without concomitant reduction in AA secretion (36) . Therefore, we cannot completely exclude the possibility that this accumulation may be partially due to impaired degradation. In any case, accumulation of APP CTFs has been shown to be neurotoxic and to cause neurodegeneration in vitro and in vivo (35, 37, 38) , and we cannot exclude the possibility that this can also contribute to the neurodegeneration observed in this family.
We further demonstrated a reduced AICD generation in cells expressing the APP I716F mutation. Amyloid precursor protein intracellular domain results from the ?-cleavage of APP A-CTF that occurs near the membrane-cytoplasm boundary (19Y21). This initial cleavage is followed by different F-cleavage events toward the middle of the transmembrane domain to generate different AA species (18) . The presence of cleavage sites at every 3 residues between the F-and ?-cleavage fits well with an >-helical model (39Y42). According to this model, the cleavage sites for AA 49 , AA 46 , AA 43 , and AA 40 are aligned on the >-helical surface of the A-CTF molecule, whereas those for AA 48 , AA 45 , and AA 42 are aligned on the other >-helical surface (39). Although we only measured the major secreted AA species, the reduction in F-and ?-cleavage and APP CTF accumulation in our study suggests that the APP I716F mutant is poorly processed by F-secretase. This is supported by a reduced activity measured by a fluorogenic assay. Taken together, our results suggest that a selective loss of function in APP proteolysis can be caused by an APP mutation. A similar loss-of-function mechanism has been proposed for PSEN mutations (43) . Consistent with this notion, a FAD-associated PSEN1 mutation was shown to slow sequential intramembrane cleavage by F-secretase and other GXGD-aspartyl proteases, resulting in longer cleavage products (44) .
Overall, this family reveals that, although the AA 42/40 ratio seems to be the best indicator of severity of the disease in patients with APP mutations, the reduced processing might also contribute to the disease process and suggests an additional mechanism by which some mutations around the F-secretase cleavage site may lead to AD.
